The treatment of ANE could significantly reduce oxidative stress and inflammation in osteoporosis, and further studies showed that ANE improved bone destruction by regulating MAPK-mediated NF-κB signaling pathway [26]. This evidence concerns the gene NFKB1 and osteoporosis.